MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.70
+0.24
+2.54%
Closed 16:00 04/09 EDT
OPEN
9.37
PREV CLOSE
9.46
HIGH
9.94
LOW
9.15
VOLUME
126.00K
TURNOVER
--
52 WEEK HIGH
20.84
52 WEEK LOW
7.32
MARKET CAP
411.92M
P/E (TTM)
-4.0336
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLLS stock price target is 37.73 with a high estimate of 73.00 and a low estimate of 11.00.

EPS

CLLS News

More
  • What Makes Cellectis S.A. (CLLS) a New Strong Buy Stock
  • Zacks · 04/02 17:00
  • Allogene Therapeutics: Revisiting Its Prospects 5 Months On
  • Seeking Alpha - Article · 03/30 07:24
  • Cellectis Enters Oversold Territory
  • Zacks · 03/27 15:09
  • Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
  • Seeking Alpha - Article · 03/25 14:02

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About CLLS

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
More

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.